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Synthesis of selective inhibitors of sphingosine
kinase 1†
Dong Jae Baek,a Neil MacRitchie,b Nigel J. Pyne,b Susan Pyneb and
Robert Bittman*a
Sphingosine kinase isoform 1 (SK1) inhibitors may serve as therapeutic
agents for proliferative diseases, including hypertension.We synthesized
a series of sphingosine-based SK1-selective inhibitors, themost potent of
which is RB-005 (IC50 = 3.6 lM), which also induced proteasomal
degradation of SK1 in human pulmonary arterial smooth muscle cells.
S1P is formed from sphingosine by two isoforms of sphingosine
kinase (SK1 and SK2) that are encoded by distinct genes and diﬀer in
their biochemical properties, subcellular localization, and function.1
Binding of S1P to 5 cell-surface G-protein coupled S1P receptors
(termed S1P1–5) induces a multitude of cell responses. S1P also has
intracellular targets.2–4 Targeting SK1 is also of particular relevance to
cancer.1 Many human tumor types exhibit increased levels of SK1
mRNA and/or protein which correlate, in several studies, with
increased tumor grade, reduced patient survival, and development
of chemotherapeutic resistance to anti-cancer agents. Indeed,
knockdown of SK1 reduces proliferation of glioblastoma cells5
and androgen-independent PC-3 prostate cancer cells.6
We have demonstrated that sustained hypoxia induces an
increase in the transcription of the SK1 gene in proliferating
human pulmonary arterial smooth muscle cells (PASMC) that
might account for their increased survival7 and thereby contribute
to vascular remodeling in pulmonary arterial hypertension (PAH).
Moreover, others have reported lower levels of ceramide in
vascular smooth muscle cells isolated from spontaneously hyper-
tensive rats,8 suggesting that hypertension is associated with
increased conversion of ceramide to sphingosine and S1P. Here,
we report the synthesis and evaluation of new sphingosine-based
SK1-selective inhibitors, which may have potential as inhibitors of
proliferative diseases, including PAH.
Several SK inhibitors have been previously identified. For example,
the non-sphingoid molecule 2-(p-hydroxyanilino)-4-(p-chlorophenyl)-
thiazole (SKi, also referred to as SKI-II; see Fig. 1) reduced intracellular
S1P, inhibited proliferation, and induced apoptosis in various cancer
cell lines.9 SKi is orally bioavailable, inhibits tumor growth10 and
ulceritive colitis,11 and reduces airway hyper-responsiveness.12
The sphingosine analogue (2R,3S,4E)-N-methyl-5-(40-pentylphenyl)-
2-aminopent-4-ene-1,3-diol (BML-258, also referred to as SK1-I;
Fig. 1) is a SK1-selective inhibitor.13
Inhibition of SK activity in cells with the non-selective isoform
inhibitors SKi,N,N-dimethylsphingosine, and FTY720 (Fig. 1) induces
proteasomal degradation and removal of SK1 from PASMC and
cancer cell lines.14–16 Removal of SK1 reduces intracellular S1P and
increases C22:0-ceramide levels, thereby promoting apoptosis.14
Scheme 1 outlines our synthetic route from 4-octylphenethyl
alcohol (1, see Scheme S1, ESI†) to a series of FTY720-like
analogues. The tertiary amines shown in Table 1 were prepared
in good yields by displacement of mesylate ion from 2 with
Fig. 1 Structures of SK inhibitors.
Scheme 1 Synthesis of tertiary amine derivatives (RB-001–010, 019 and 020)
and quaternary ammonium salts (RB-011–018) of FTY720. (a) MsCl, Et3N, CH2Cl2;
(b) MeI, K2CO3, MeCN.
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amines in acetonitrile. Some of the quaternary ammonium
salts were prepared by N-alkylation of the tertiary amines
(and the secondary amine RB-006) with an excess of MeI and
K2CO3 in acetonitrile (Scheme S2, ESI†), whereas others (RB-
011, RB-012, RB-017, and RB-018) were prepared by N-alkylation
of 2 with tertiary N-methylamines (see ESI†).
We have established SK1 and SK2 assays using sphingosine/
[32P]-ATP with over-expressed recombinant SK1 in HEK 293 cell
lysates or purified SK2.15,16 By using sphingosine concentra-
tions of 3 mM and 10 mM, which correspond to the Km values
of SK116 and SK2,17 respectively, we demonstrate here that
RB-001–003, RB-005, RB-007–009, RB-019 (Table 1), and RB-021
(Scheme 2) are selective inhibitors of SK1 over SK2.
The data in Fig. 2 show that the lead molecules for further
structural optimization are 1-(4-octylphenethyl)piperidin-4-ol (RB-
005) and 1-(4-octylphenethyl)piperidin-3-ol (RB-019) because these
compounds have the highest selectivity for SK1 over SK2 (15.0- and
6.1-fold, respectively). These compounds feature an n-octylphenyl
group linked in a 2-carbon tether to the nitrogen of 4-hydroxy- or
3-hydroxypiperidine, respectively. Small changes in the structure of
this tertiary amine result in large changes in selectivity, arguing for the
hypothesis that RB-005 is a highly selective inhibitor of SK1. The
hydroxyl group in the heterocyclic ring is important for inhibition of
SK1 by RB-005. Replacement of the 4-OH groupwith a 4-methyl group
aﬀords RB-004, which is a moderate inhibitor of both SK1 and SK2;
the 3-OH regioisomer RB-019 is a selective but less potent SK1
inhibitor. The size of the heterocycle is important as RB-003 is less
selective than RB-005. The hydrophobic alkyl chain is also a key
feature as sulfonation18 in this region reduces inhibition of SK1; the
sulfones RB-021 andRB-022were prepared by Sonogashira reaction of
alkyne 3 with 2-(4-bromophenyl)-ethanol, followed by catalytic hydro-
genation and mesylation of 4, and finally reaction with piperidine or
Table 1 Synthesized compounds for evaluation as SK inhibitors
Compound R Compound R
RB-001 RB-011
RB-002 RB-012
RB-003 RB-013
RB-004 RB-014
RB-005 RB-015
RB-006 RB-016
RB-007 RB-017
RB-008 RB-018
RB-009 RB-019
RB-010 RB-020
Scheme 2 Synthesis of phenylsulfone analogues of RB-021 and RB-022. (a)
PhSO2Na, THF, DMF; (b) 2-(4-bromophenyl)-ethanol, Pd(PPh3)4, CuI, Et3N; (c) 10%
Pd/C, H2, EtOAc; (d) MsCl, Et3N, CH2Cl2; (e) piperidine or 4-OH-piperidine, MeCN.
Fig. 2 Eﬀect of inhibitors on SK1 or SK2 activity. SK1 activity was measured using
3 mM sphingosine and 250 mMATP. SK2 activity was assayed using 10 mM sphingosine
and 250 mMATP (n = 3 for each compound, results expressed asmean inhibition SD).
RB series compounds were used at 50 mM. BML-258 (50 mM) inhibited SK1 activity by
74.5  3.3% (n = 3). The control is 100% and equals activity against Sph alone.
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its 4-hydroxy derivative (Scheme 2 and Scheme S3, ESI†). Conversion
of the heterocyclic amines RB-003–RB-006 by N-methylation to the
corresponding quaternary ammonium compounds, RB-013–RB-016,
reduces inhibition of both SK1 and SK2 (Fig. 2). Relocation of
the quaternary nitrogen functionality to an exocyclic position as in
RB-016–RB-018 also aﬀorded nonselective SK inhibitors (Fig. 2). This
contrasts with a study that suggested that quaternary ammonium
compounds are selective inhibitors of SK2 over SK1.19 The length of
the intervening C–C link between the benzene ring and heterocyclic
ring remains to be examined.
Next, the possibility that the six inhibitors bearing a hydroxyl
group may also serve as SK substrates was examined. At 50 mM,
none of these compounds are SK substrates, with the exception of
RB-020, which is a weak substrate of SK1 but a good substrate of
SK2 (Table 2), and RB-019, which is a very weak substrate of SK2
(o10% of Sph, data not shown).
RB-020 is less eﬃciently phosphorylated by SK1 than sphingo-
sine, and probably overlaps the catalytic site of SK1 to inhibit
phosphorylation of sphingosine (Table 2). However, this is not the
case for SK2 where phosphorylation of sphingosine and RB-020
appear mutually exclusive (Table 2). RB-019 also inhibits SK1 activity
against sphingosine (Fig. 2). Both RB-019 and RB-020 contain a
hydroxyl group that is likely to be phosphorylated by SK (Table 2). It
is noteworthy that RB-020 has a primary hydroxyl group attached to
the heterocyclic ring through a 4-CH2 group, while RB-019 has a
secondary hydroxyl group directly attached to C-3 of the heterocyclic
ring; therefore, the latter hydroxyl group may be too far removed
from the catalytic determinants of SK1 to be phosphorylated, but
probably overlaps the substrate binding site to inhibit SK1 activity.
RB-008 and RB-009 have a second N atom in the heterocyclic ring,
and also possess a –(CH2)2OH and –(CH2)3OH group, respectively.
However, RB-008 and RB-009 are not substrates for SK1 or SK2 (data
not shown) but are inhibitors of SK1 (Fig. 2).
RB-005 inhibited SK1 activity with an IC50 value of 3.6 0.38 mM
(Fig. 3A). Finally, to examine whether RB-005 may function as more
than a reversible inhibitor of SK1 activity, we assessed its ability to
promote the proteasomal degradation of SK1 in cells.
Importantly, we found that treatment of PASMC with RB-005
(10 mM, 24 h) reduced the expression of SK1. In common with
(S)-FTY720 vinylphosphonate,16 the eﬀect of RB-005 on SK1
expression was reversed by pre-treatment of the cells with the
proteasomal inhibitor MG132 (Fig. 3B).
We conclude that the FTY720 scaﬀold can produce selective SK1
inhibitors with low mM potency and which also induce the protea-
somal degradation of SK1 in cells. Therefore, RB-005 represents a
molecule for optimization to produce eﬀective therapeutic agents.
This work was supported by a British Heart Foundation
grant (29476) to NJP/SP and by NIH Grant HL-083187 to RB.
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Table 2 RB-020 (50 mM) is a substrate of SK1 and SK2 and an inhibitor of SK1
activity against sphingosine (Sph)a
SK1 activity (% control) SK2 activity (% control)
Sph 100  4.4 100  12.8
Sph + RB-020 34.4  4.1 315  5.1
RB-020 27.5  3.0 228  17.9
a Sph was used at 3 and 10 mM for SK1 and SK2, respectively. Results are
represented as % activities  SD (n = 3 assays) of control (where 100%
equals activity against Sph alone).
Fig. 3 Eﬀect of RB-005 on SK1 activity and expression. (A) Concentration-dependent
inhibition of SK1 activity by RB-005 using 3 mM sphingosine and 250 mM ATP (results
expressed as mean inhibition  SD of control) (n = 3, the control is 100% and equals
activity against sphingosine alone). (B) Eﬀects of RB-005 on SK1 down-regulation.
PASMC were treated with or without MG132 (10 mM, 30 min) before RB-005 (10 mM,
24 h). Cell lysates werewestern blottedwith anti-SK1 and -actin antibodies. Results are
representative of three experiments.
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